23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million

The New York Times - Business:

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.

Author: Michael Levenson

This post first appeared in The New York Times - Business. Read the original article.